ID   KMS-21-PE
AC   CVCL_A445
SY   KMS-21PE; KMS21PE; Kawasaki Medical School-21-Pleural Effusion
DR   CGH-DB; 31-1
DR   CGH-DB; 9142-4
DR   Wikidata; Q54900173
RX   DOI=10.1002/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B;
RX   PubMed=11697507;
RX   PubMed=15215163;
CC   Population: Japanese.
CC   Omics: Variations; Array-based CGH.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 10-04-25; Version: 18
//
RX   DOI=10.1002/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B;
RA   Otsuki T., Yamada O., Yata K., Nakazawa N., Taniwaki M., Sakaguchi H.,
RA   Yawata Y., Ueki A.;
RT   "Genetic and biological characterization of human myeloma cell lines:
RT   an overview of the lines established at Kawasaki Medical School.";
RL   Gene Funct. Dis. 1:48-56(2000).
//
RX   PubMed=11697507; DOI=10.3109/10428190109099339;
RA   Otsuki T., Wada H., Nakazawa N., Taniwaki M., Kouguchi K., Ohkura M.,
RA   Uehira K., Isoda K., Yata K., Sakaguchi H., Yawata Y., Ueki A.,
RA   Yamada O.;
RT   "Establishment of CD7+ human myeloma sister cell lines, KMS-21-PE and
RT   KMS-21-BM, carrying t(11;14) and t(8;14).";
RL   Leuk. Lymphoma 42:761-774(2001).
//
RX   PubMed=15215163; DOI=10.1016/S0002-9440(10)63276-2; PMCID=PMC1618545;
RA   Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S.,
RA   Taniwaki M., Inazawa J.;
RT   "Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be
RT   associated with drug-resistance phenotype in multiple myeloma.";
RL   Am. J. Pathol. 165:71-81(2004).
//